Atopic dermatitis: emerging therapies
- PMID: 28895959
- DOI: 10.12788/j.sder.2017.0137
Atopic dermatitis: emerging therapies
Abstract
Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.
©2017 Frontline Medical Communications.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources